Today’s news reports cover such matters as:
- Genistein as a prostate cancer stimulating agent
- Molecular characterization of advanced prostate cancers
- Imaging technology and focal therapy
Genistein has long been considered to have potential as a chemopreventive agent. However, El Touny and Banerjee have now shown that genistein also has the potential to induce growth of aggressive forms of prostate cancer in laboratory and animal models of the disease.
Another new paper has indicated the potential of molecular classification of prostate cancers using “gene expression signatures.” Wang et al. hypothesized that bone cell (“osteoblast’)-derived factors promote hormonal progression of prostate cancer cells, and identified the gene expression signature of prostate cancer exposed to such osteoblast-derived factors. This gene expression signature had specificity for prostate cancer and could resolve clinical specimens according to stage (benign, localized, and metastatic) and androgen sensitivity with accuracies of 100 percent and 80 percent, respectively. Their results suggest that factors derived from osteoblasts induce an advanced form of prostate cancer and promote hormonal progression.
Turkbey et al. have published yet another review of the potential utility of advanced imaging technology as a means to help identify patients who may be appropriate for focal therapy. The “New” Prostate Cancer InfoLink thinks it is time that some appropriate organization set down standards for the minimal criteria defining patients who are appropriate for focal therapy and the methods considered appropriate to characterize such patients with sufficient accuracy.